Exon Skipping Efficacy and Dosing Frequency Competition

Dyne Therapeutics (DYN)'s zeleciment rostudirsen (DYNE-251) is an antibody-oligonucleotide conjugate (AOC) targeting transferrin receptor 1 and exon 51. Based on the results from its Phase 1/2 clinical trial, it has been granted FDA priority review. The Prescription Drug User Fee Act (PDUFA) decision date is set for January 2027. If approved, it will directly compete with Sarepta Therapeutics' eteplirsen (Exondys 51), which is administered intravenously once a week. Once-monthly administration and higher dystrophin expression are key differentiators that could drive product switching within the same mutation group.

Follow-on Gene Therapies and Safety Standards

REGENXBIO (RGNX)'s RGX-202 is a Phase 3 gene therapy that delivers micro-dystrophin using an NAV AAV8 vector. In the pivotal trial, over 93% of patients at week 12 achieved the 10% micro-dystrophin expression threshold. The company plans to submit a Biologics License Application (BLA) in the third quarter of 2026, with an FDA decision expected in 2027. Solid Biosciences (SLDB)'s SGT-003 has also initiated Phase 3 dosing. While Sarepta's marketed gene therapy, Elevidys (delandistrogene moxeparvovec-rokl, AAVrh74 micro-dystrophin), serves as the benchmark, the FDA's addition of a boxed warning in November 2025 regarding the risk of acute liver failure and the restriction of the indication to ambulatory patients aged 4 and older has made the safety and immunogenicity data of later entrants critical for commercial success.

Expansion of Mutation-Agnostic Therapies

Satellos Bioscience (MSCL)'s SAT-3247 is a Phase 2 small molecule targeting AAK1 to modulate muscle stem cell regeneration. In four adult patients, the average muscle fat fraction decreased from 49.7% to 46.0% over six months, and the upper limb maximum voluntary contraction index TE99C improved by approximately 34%. Keros Therapeutics (KROS)'s rinvatercept (KER-065) is an activin receptor IIA/IIB ligand trap that inhibits myostatin and activin A, with initial Phase 2 results expected in early 2027. Both candidates offer a universal treatment strategy that is not limited by specific exons or AAV eligibility and can be used in combination with corticosteroids, vamorolone, and givinostat.

Approved Products and Regulatory Hurdles

The FDA approved Agamree (vamorolone, a glucocorticoid receptor agonist) on October 26, 2023, and Duvyzat (givinostat, an HDAC inhibitor) on March 21, 2024. Both drugs are mutation-agnostic and represent commercial competition. However, Capricor Therapeutics (CAPR)'s allogeneic cardiosphere-derived cell therapy, deramiocel, was resubmitted after receiving a complete response letter from the FDA in 2025, but the advisory committee voted 9 to 3 against the evidence of efficacy on July 29, 2026. The PDUFA decision date of August 22, 2026, will make the consistency of cardiac and upper limb function endpoints and statistical analysis plans key regulatory considerations for late-stage DMD development.

Sales Validation and Major Deals

In 2025, Sarepta reported Elevidys sales of $898.7 million and combined sales of $965.6 million for Exondys 51, Vyondys 53, and Amondys 45, demonstrating the substantial commercial potential of the U.S. DMD franchise. Novartis (NVS) acquired Avidity Biosciences for $12 billion on February 27, 2026, based on a fully diluted basis, securing del-desiran (AOC 1044), an AOC candidate targeting exon 44. Servier agreed to acquire Edgewise Therapeutics (EWTX)'s neuromuscular disease business and sevasemten, a fast-skeletal muscle myosin inhibitor, for an upfront payment of $1.55 billion and up to $1.1 billion in regulatory and commercial milestone payments, demonstrating that the value of DMD assets is determined not only by clinical stage but also by mutation-agnosticism and safety differentiation.